Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print

Latest Articles in Remdesivir

Cipla To Price Remdesivir Version For COVID-19 Under 5,000 Rupees

The expectations suggest sales of between $2 billion and $3 billion between 2020 and 2021 at a price of $1,000 to $2,000 per course, according to Jefferies analyst Michael Yee.

Read More

Glenmark, Cipla Stocks Surge After Nod To Launch Drugs For Mild-to-moderate COVID-19 Infections

At the same time, Cipla's stock jumped by 4.3 per cent to Rs 664.45 per unit after it announced the launch of remdesivir under its brand name Cipremi.

Read More

Remdesivir included in 'investigational therapy' for restricted emergency use on COVID-19 patients: Health Ministry

Remdesivir included in 'investigational therapy' for restricted emergency use on COVID-19 patients: Health Ministry

Read More

Six Indian companies applied to CDSCO for permission to manufacture, market Remdesivir drug: Health Ministry

Six Indian companies applied to CDSCO for permission to manufacture, market Remdesivir drug: Health Ministry

Read More

Zydus signs licensing agreement with Gilead to manufacture and market Remdesivir

Zydus signs licensing agreement with Gilead to manufacture and market Remdesivir

Read More

Hetero Signs Agreement With Gilead Sciences For Manufacturing & Distribution Of ‘Remdesivir’ In 127 Countries, Including India For COVID-19

Under this licensing deal, Hetero will be supplying Remdesivir in 127 countries, including India, subject to regulatory approvals in respective countries.

Read More